Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Eikon Therapeutics presented updated TeLuRide-005 data for its TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line stage 4 NSCLC at the 2026 ESMO Congress. In the squamous cohort, ORR was 72.4% with a 100% disease control rate and a 12.9-month median duration of response; pooled efficacy-evaluable data showed 63.1% ORR and 89.2% DCR. Tolerability was broadly similar to standard of care — 48.6% Grade 3+ TRAEs, 6.9% discontinuations, no treatment-related deaths — supporting outpatient systemic administration, a key differentiator versus prior TLR7/8 agents. The registrational Phase 2/3 TeLuRide-008 trial is actively enrolling, with a prespecified dose-selection interim analysis expected in 2H 2027.

•6d ago

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Eikon Therapeutics presented initial and updated Phase 1/2 data for its three clinical programs — PARP1-selective inhibitors EIK1003 and EIK1004 and WRN helicase inhibitor EIK1005 — at the 2026 ESMO Congress in Madrid. EIK1003 showed manageable safety and preliminary antitumor activity in monotherapy and combination cohorts, with ORRs of 14.3% in HRR-mutant monotherapy, 20.8% with abiraterone in prostate cancer, and 26.4% with weekly paclitaxel in ovarian/breast cancer. CNS-penetrant EIK1004 demonstrated minimal hematologic toxicity with no dose-limiting toxicities across 68 dosed participants, and WRN inhibitor EIK1005 was well tolerated with a PK profile supporting weekly dosing. The data support continued development of all three programs, with additional combination and dose-optimization readouts expected in 2027.

•9d ago

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

Eikon Therapeutics submitted an IND application to the FDA to evaluate EIK1006, a novel androgen receptor antagonist, for advanced metastatic prostate cancer. EIK1006 is structurally unrelated to existing lutamide-class antagonists and was optimized against wild-type and clinically relevant AR variants using Eikon's single-molecule imaging platform. The IND is an early development milestone; clinical testing, FDA clearance, and any data readouts remain ahead, with Eikon also pointing to anticipated 2026 ESMO Congress presentations.

•17d ago

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

Eikon Therapeutics (Nasdaq: EIKN) appointed Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Chang joins from Bristol Myers Squibb, where he led Cardiovascular Discovery Biology and Translational Pharmacology, after prior roles at Gilead Sciences and MyoKardia, where his disease-biology work on mavacamten contributed to the drug's later approval for hypertrophic cardiomyopathy. Chairman and CEO Roger Perlmutter said Chang's scientific judgment and translational expertise will be invaluable as Eikon applies its discovery platform, with the hire coming as the company's late-stage oncology portfolio advances.

•1mo ago

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics reported a Q2 net loss of $88.4 million, narrowing from $105.2 million in the prior year, with a robust cash position of $531.2 million that is expected to fund operations into the second half of 2027. The company announced a key clinical milestone, confirming that the independent Data Monitoring Committee completed the first interim analysis of the Phase 2/3 TeLuRide-006 trial of EIK1001, recommended continuation, and selected a dosing regimen for expansion. Additionally, Eikon appointed Ma. Fatima Francisco to its Board of Directors and noted that seven abstracts covering its clinical pipeline have been accepted for presentation at the upcoming ESMO Congress.

•2mo ago

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Eikon Therapeutics selected a 0.60 mg/m(2) dose for its TeLuRide-006 Phase 2/3 trial of EIK1001 in advanced melanoma, following a recommendation from the independent Data Monitoring Committee. The DMC reviewed unblinded data and advised that the study continue as planned, clearing the path for the registrational portion of the trial. EIK1001 is a TLR7 and 8 dual agonist being evaluated in combination with pembrolizumab as a first-line therapy for advanced cutaneous melanoma.

•2mo ago

Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board

Eikon Therapeutics appointed Johnny Bennett, Ph.D., Vice President and Head of Discovery Chemistry at Merck Research Laboratories, to its Scientific Advisory Board. Dr. Bennett’s appointment builds on an existing relationship where Merck supplies KEYTRUDA for Eikon’s trials of EIK1001 and EIK1005, further solidifying strategic ties between the companies. Bennett brings significant drug discovery experience, including the discovery of sugammadex (Bridion), and joins a board featuring multiple Nobel laureates.

•2mo ago

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Eikon Therapeutics dosed the first patient in TeLuRide-008, a registrational Phase 2/3 study evaluating EIK1001 combined with pembrolizumab and chemotherapy for first-line Stage 4 Non-Small Cell Lung Cancer. This marks the second registrational trial for EIK1001, following the initiation of TeLuRide-006 in advanced malignant melanoma in May 2025. EIK1001 is a dual-agonist of Toll-like receptors 7 and 8 studied in over 500 patients to date, designed to stimulate both innate and adaptive immunity.

•3mo ago

Eikon Therapeutics to Join the Russell 3000® Index

Eikon Therapeutics announced it will be added to the broad-market Russell 3000 Index effective after the market closes on June 26, 2026. The index measures the performance of approximately 3,000 stocks, representing 98% of the investable US equity market, and undergoes annual reconstitution. Inclusion in the benchmark typically triggers buying from passive funds tracking the index and increases visibility among institutional investors.

•4mo ago

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics presented updated Phase 2 data for EIK1001 in first-line stage 4 NSCLC at ASCO 2026, showing a 63.1% objective response rate and 90.8% disease control rate in combination with pembrolizumab and chemotherapy. The data included a 72.4% ORR in the squamous cohort and a 55.6% ORR in the non-squamous cohort, with a manageable safety profile supporting outpatient administration. Eikon also reported initial combination data for EIK1003, a selective PARP1 inhibitor, showing a 24.5% ORR in platinum-resistant ovarian and HER2-negative breast cancer when combined with weekly paclitaxel.

•5mo ago

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon Therapeutics will present six abstracts at the 2026 ASCO Annual Meeting in Chicago, starting May 29. The presentations cover clinical progress for its lead programs: EIK1001 (TLR7/8 dual agonist) in NSCLC and melanoma, EIK1003 (PARP1 inhibitor) in solid tumors, and EIK1005 (WRN inhibitor) in early development. Data includes efficacy and safety results from Phase 2/3 trials for EIK1001 and initial combination/monotherapy results for EIK1003, alongside first-in-human safety data for EIK1005.

•5mo ago